Study introduces a novel approach to mapping protein-receptor interactions

One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells.

Cardiac rehabilitation still underutilized despite proven benefits

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

November 23, 2023

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program | Psychedelic Invest

Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Study introduces a novel approach to mapping protein-receptor interactions

Cardiac rehabilitation still underutilized despite proven benefits

SfN 2024: Where neuroscience meets community, collaboration, and innovation

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program | Psychedelic Invest

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe